CAPTRUST Financial Advisors
CARM

CAPTRUST Financial Advisors’s Carisma Therapeutics CARM Stock Holding History

CAPTRUST Financial Advisors’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-150
Closed -$2K – 2363
2022
Q2 		$2K Hold
150
– – ﹤0.01% 4433
2022
Q1 		$2K Hold
150
– – ﹤0.01% 4464
2021
Q4 		$2K Hold
150
– – ﹤0.01% 4391
2021
Q3 		$2K Buy
+150
New +$7.2K ﹤0.01% 4237

Other funds holding CARM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return

CAPTRUST Financial Advisors's CARM Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of Carisma Therapeutics (CARM) in Q3 2022, closing a stake of 150 shares — an estimated $2K sold.

CAPTRUST Financial Advisors first reported a position in CARM in Q3 2021 and held it in 4 quarters. The position peaked at $2K in Q2 2022. 68 funds tracked by Wall St. Rank hold CARM as of Q3 2022.

  • CAPTRUST Financial Advisors reported no remaining Carisma Therapeutics position as of Q3 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 150 Carisma Therapeutics shares in Q3 2022, an estimated $2K.
  • CAPTRUST Financial Advisors first reported a position in Carisma Therapeutics in Q3 2021 and held it in 4 quarters.
  • CAPTRUST Financial Advisors's Carisma Therapeutics position peaked at $2K in Q2 2022.
  • 68 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.